BR112019004470A2 - métodos para detectar a expressão de pd-l1 por células e usos do mesmo - Google Patents
métodos para detectar a expressão de pd-l1 por células e usos do mesmoInfo
- Publication number
- BR112019004470A2 BR112019004470A2 BR112019004470A BR112019004470A BR112019004470A2 BR 112019004470 A2 BR112019004470 A2 BR 112019004470A2 BR 112019004470 A BR112019004470 A BR 112019004470A BR 112019004470 A BR112019004470 A BR 112019004470A BR 112019004470 A2 BR112019004470 A2 BR 112019004470A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- expression
- cell
- detecting
- cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 239000006285 cell suspension Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1486—Counting the particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
métodos para a detecção da expressão do ligante 1 de morte programada por célula (pd-l1) de células de neoplasia. aspectos dos métodos incluem análise citométrica de uma suspensão de células marcadas para quantificar a expressão de pd-l1 de célula para detectar se uma célula neoplásica que expressa pd-l1 acima de um limite predeterminado está presente na amostra de neoplasia. além disso, são também providos kits que encontram uso na prática dos métodos em questão.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662384037P | 2016-09-06 | 2016-09-06 | |
PCT/US2017/050322 WO2018048936A1 (en) | 2016-09-06 | 2017-09-06 | Methods of detecting per cell pd-l1 expression and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019004470A2 true BR112019004470A2 (pt) | 2019-09-03 |
Family
ID=61561676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019004470A BR112019004470A2 (pt) | 2016-09-06 | 2017-09-06 | métodos para detectar a expressão de pd-l1 por células e usos do mesmo |
Country Status (11)
Country | Link |
---|---|
US (1) | US10782298B2 (pt) |
EP (1) | EP3510378A4 (pt) |
JP (2) | JP2019535001A (pt) |
CN (2) | CN109906367A (pt) |
BR (1) | BR112019004470A2 (pt) |
CA (1) | CA3036278A1 (pt) |
CR (1) | CR20190172A (pt) |
IL (1) | IL265175A (pt) |
MX (1) | MX2019002578A (pt) |
SG (1) | SG11201901991QA (pt) |
WO (2) | WO2018048936A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11726089B2 (en) | 2016-09-06 | 2023-08-15 | Incelldx, Inc. | Methods of assaying neoplastic and neoplasia-related cells and uses thereof |
JP2019535001A (ja) | 2016-09-06 | 2019-12-05 | インセルディーエックス・インコーポレーテッド | 細胞あたりのpd−l1発現量を検出する方法及びその使用 |
EP3853610B1 (en) * | 2018-09-20 | 2024-05-22 | Ventana Medical Systems, Inc. | Size-based gating to analyze flow cytometry data |
CA3119311A1 (en) * | 2018-11-09 | 2020-05-14 | Pierian Biosciences, LLC | Methods and compositions for determining the composition of a tumor microenvironment |
US20220107320A1 (en) * | 2019-02-15 | 2022-04-07 | Incelldx, Inc. | Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein |
CN110142068B (zh) * | 2019-06-12 | 2024-02-02 | 杭州华得森生物技术有限公司 | 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法 |
CN111735955A (zh) * | 2020-04-20 | 2020-10-02 | 山东省肿瘤防治研究院(山东省肿瘤医院) | 一种肝细胞癌患者外周血循环肿瘤细胞上pd-l1表达的免疫荧光检测方法 |
EP4305174A1 (en) * | 2021-03-10 | 2024-01-17 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | Reporter cells expressing chimeric polypeptides for use in determining presence and or activity of immune checkpoint molecules |
CN113358872B (zh) * | 2021-06-03 | 2022-10-21 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 用于评估肿瘤免疫治疗疗效的标志物组及*** |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004061458A2 (en) * | 2003-01-03 | 2004-07-22 | Aurelium Biopharma Inc. | Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
MX2007004176A (es) * | 2004-10-06 | 2007-06-15 | Mayo Foundation | B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer. |
JPWO2007136026A1 (ja) * | 2006-05-19 | 2009-10-01 | 忠和 鄭 | 抗原タンパク質の定量方法及び定量用キット |
JP6448533B2 (ja) * | 2012-05-15 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Pd−1/pd−l1シグナル伝達を破壊することによる癌免疫療法 |
AR095363A1 (es) | 2013-03-15 | 2015-10-14 | Genentech Inc | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 |
WO2015034820A1 (en) * | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
PL3702373T3 (pl) | 2013-09-13 | 2022-12-05 | Beigene Switzerland Gmbh | Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne |
EP3060919A4 (en) * | 2013-10-25 | 2018-02-14 | Nodality, Inc. | Methods and compositions for immunomodulation |
JP6355154B2 (ja) * | 2014-04-03 | 2018-07-11 | 公益財団法人ヒューマンサイエンス振興財団 | 診断補助方法 |
TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對pd-l1之抗體分子及其用途 |
EP3207377A4 (en) * | 2014-10-15 | 2018-05-02 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for therapy targeting pd-l1 |
TWI721008B (zh) * | 2015-09-01 | 2021-03-11 | 中央研究院 | 具拮抗pdl1功能的適體分子於癌症治療之應用 |
LT3368683T (lt) | 2015-10-27 | 2020-04-10 | Pharmassist Ltd | Pd-l1 kiekybinio įvertinimo būdas |
JP2019535001A (ja) | 2016-09-06 | 2019-12-05 | インセルディーエックス・インコーポレーテッド | 細胞あたりのpd−l1発現量を検出する方法及びその使用 |
-
2017
- 2017-09-06 JP JP2019512878A patent/JP2019535001A/ja not_active Ceased
- 2017-09-06 SG SG11201901991QA patent/SG11201901991QA/en unknown
- 2017-09-06 CR CR20190172A patent/CR20190172A/es unknown
- 2017-09-06 EP EP17849473.8A patent/EP3510378A4/en active Pending
- 2017-09-06 BR BR112019004470A patent/BR112019004470A2/pt not_active Application Discontinuation
- 2017-09-06 CN CN201780063086.4A patent/CN109906367A/zh active Pending
- 2017-09-06 MX MX2019002578A patent/MX2019002578A/es unknown
- 2017-09-06 CA CA3036278A patent/CA3036278A1/en not_active Abandoned
- 2017-09-06 WO PCT/US2017/050322 patent/WO2018048936A1/en unknown
-
2018
- 2018-01-03 US US15/861,352 patent/US10782298B2/en active Active
-
2019
- 2019-01-02 WO PCT/US2019/012074 patent/WO2019136082A1/en active Application Filing
- 2019-01-02 CN CN201980016405.5A patent/CN112088309A/zh active Pending
- 2019-03-05 IL IL265175A patent/IL265175A/en unknown
-
2022
- 2022-06-14 JP JP2022096028A patent/JP2022133307A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2019002578A (es) | 2019-09-18 |
US20180136214A1 (en) | 2018-05-17 |
WO2018048936A1 (en) | 2018-03-15 |
EP3510378A1 (en) | 2019-07-17 |
CR20190172A (es) | 2019-06-13 |
CA3036278A1 (en) | 2018-03-15 |
JP2022133307A (ja) | 2022-09-13 |
CN112088309A (zh) | 2020-12-15 |
JP2019535001A (ja) | 2019-12-05 |
IL265175A (en) | 2019-05-30 |
US10782298B2 (en) | 2020-09-22 |
WO2019136082A1 (en) | 2019-07-11 |
CN109906367A (zh) | 2019-06-18 |
EP3510378A4 (en) | 2020-07-08 |
SG11201901991QA (en) | 2019-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019004470A2 (pt) | métodos para detectar a expressão de pd-l1 por células e usos do mesmo | |
BR112018069849A2 (pt) | kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático | |
BR112022024755A2 (pt) | Composição, kit e método para detectar sars-cov-2 e uso dos mesmos | |
MX366275B (es) | Metodos para detectar y medir la agregacion. | |
GB2519906A (en) | Methods and systems for detecting biological components | |
MX369055B (es) | Dispositivo de recogida de fluidos biológicos y sistema de recogida y ensayo de fluidos biológicos. | |
BR112017021256A2 (pt) | dispositivos e métodos para a análise de amostras | |
BR112016010510A2 (pt) | método, arranjo e uso do mesmo | |
GB2526736A (en) | Methods, compositions, and kits for nucleic acid analysis | |
BR112016008970A2 (pt) | Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra | |
BR112014011818A2 (pt) | método para realizar ensaios de quantificação | |
MX2015014479A (es) | Dispositivo de transferencia de muestras de fluidos biologicos y sistema de separacion y analisis de fluidos biologicos. | |
MX2017015011A (es) | Ensayo a base de celulas para detectar homodimeros anti-cd3. | |
BR112016016249A2 (pt) | Métodos de análise imunocromatográfica, dispositivo de análise imunocromatográfica e kit | |
BR112016019836A2 (pt) | método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito | |
BR112017009151A2 (pt) | ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos | |
BR112016021929A2 (pt) | Método, dispositivo e conjunto para a avaliação da qualidade de uma amostra de produto, conjunto de dados, meio de armazenamento de dados, uso dos rotuladores e método para o fornecimento de uma coleção de produtos | |
MX2015014482A (es) | Dispositivo de separacion de fluidos biologicos y sistema de separacion y analisis de fluidos biologicos. | |
MX2015014473A (es) | Dispositivo de separacion de fluido biologico y sistema de separacion y analisis de fluido biologico. | |
BR112016007251A2 (pt) | método de processamento de biomassa que contém celulose | |
BR112014031182A2 (pt) | método para testar uma formação, sistema para testar a pressão de uma formação e meio de armazenamento legível por computador | |
MX2015013310A (es) | Metodo y reactivo para determinar metabolitos de la vitamina d. | |
MX2015014478A (es) | Dispositivo de transferencia de fluidos biologicos y sistema de muestreo de fluidos biologicos. | |
BR112017011026A2 (pt) | métodos analíticos e arranjos para uso nos mesmos | |
BR112015027553A8 (pt) | pipeta para obter um espécime, montagem, cartucho e método para preparar um espécime |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |